(Reuters)- Pfizer Inc (NYSE :) and its partner BioNTechSe will offer volunteers who received placebo in the COVID-19 vaccine trial the option to receive the first dose of the vaccine by March 1, 2021 during the trial. is.
The study’s vaccine transfer option allows all participants 16 years and older to see if they have been given a placebo. “Participants who learn that they have been given a placebo have the option of receiving the study vaccine during the trial.” The two companies have stated on their website https://www.covidvaccinestudy.com/participants for test participants.
The U.S. Food and Drug Administration and a committee of its external advisors have expressed concern about Pfizer’s “blind” program and gathered data on the safety and efficacy needed to obtain full FDA approval for the vaccine. He said it could be difficult to continue.
Participants who received placebo will book two trial vaccines within the trial, the companies said on their websites.
“The investigators will follow the latest guidance from the US Centers for Disease Control and Prevention and local health authorities to give participants priority vaccine migration options,” the two companies said.
Fusion media Alternatively, anyone involved with Fusion Media will not be liable for any loss or damage resulting from relying on the data, quotes, charts, trading signals and other information contained on this website. Please be fully informed about the risks and costs associated with trading in financial markets. This is one of the most risky forms of investment possible.
Pfizer and BioNTech provide COVID vaccine to Reuters placebo-inoculated volunteers
https://www.investing.com/news/stock-market-news/pfizer-and-biontech-to-offer-covid-vaccine-to-volunteers-who-got-placebo-2378430 Pfizer and BioNTech provide COVID vaccine to Reuters placebo-inoculated volunteers